NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $75 | +92.3% | 124,750 | +87.2% | 0.00% | – |
| Q2 2023 | $39 | -80.8% | 66,650 | -76.8% | 0.00% | – |
| Q1 2023 | $203 | -65.2% | 287,670 | +11.6% | 0.00% | – |
| Q4 2022 | $583 | -99.9% | 257,874 | -1.4% | 0.00% | – |
| Q3 2022 | $838,000 | -21.0% | 261,627 | -6.3% | 0.00% | – |
| Q2 2022 | $1,061,000 | +89.5% | 279,255 | +168.6% | 0.00% | – |
| Q1 2022 | $560,000 | -55.9% | 103,980 | +10.7% | 0.00% | – |
| Q4 2021 | $1,269,000 | -44.2% | 93,951 | -25.8% | 0.00% | – |
| Q3 2021 | $2,275,000 | -74.2% | 126,645 | -75.4% | 0.00% | -100.0% |
| Q2 2021 | $8,820,000 | -17.1% | 513,965 | -3.4% | 0.00% | 0.0% |
| Q1 2021 | $10,643,000 | +14.1% | 532,164 | -3.0% | 0.00% | 0.0% |
| Q4 2020 | $9,331,000 | -49.7% | 548,893 | -50.9% | 0.00% | -50.0% |
| Q3 2020 | $18,552,000 | -38.0% | 1,118,260 | -13.4% | 0.00% | -50.0% |
| Q2 2020 | $29,909,000 | +19.3% | 1,291,400 | -8.1% | 0.00% | 0.0% |
| Q1 2020 | $25,072,000 | +17.9% | 1,404,610 | +42.6% | 0.00% | +33.3% |
| Q4 2019 | $21,262,000 | -20.6% | 985,053 | -33.0% | 0.00% | -25.0% |
| Q3 2019 | $26,763,000 | -43.2% | 1,469,308 | +11.0% | 0.00% | -42.9% |
| Q2 2019 | $47,091,000 | +0.4% | 1,323,527 | -5.2% | 0.01% | 0.0% |
| Q1 2019 | $46,921,000 | -6.8% | 1,396,464 | -8.8% | 0.01% | -22.2% |
| Q4 2018 | $50,331,000 | -53.5% | 1,531,212 | -13.7% | 0.01% | -43.8% |
| Q3 2018 | $108,158,000 | +15.1% | 1,774,243 | -7.8% | 0.02% | +14.3% |
| Q2 2018 | $93,962,000 | -72.0% | 1,924,277 | -39.1% | 0.01% | -73.6% |
| Q1 2018 | $335,594,000 | +203.7% | 3,158,233 | +70.7% | 0.05% | +194.4% |
| Q4 2017 | $110,520,000 | +291.2% | 1,850,629 | +57.2% | 0.02% | +260.0% |
| Q3 2017 | $28,248,000 | +44.6% | 1,177,005 | +17.8% | 0.01% | +25.0% |
| Q2 2017 | $19,541,000 | -35.3% | 999,525 | -22.4% | 0.00% | -33.3% |
| Q1 2017 | $30,212,000 | +102.0% | 1,287,250 | +5.6% | 0.01% | +100.0% |
| Q4 2016 | $14,953,000 | -24.7% | 1,218,700 | +5.4% | 0.00% | -25.0% |
| Q3 2016 | $19,867,000 | +138.9% | 1,156,400 | +97.8% | 0.00% | +100.0% |
| Q2 2016 | $8,317,000 | +26.3% | 584,500 | +22.1% | 0.00% | +100.0% |
| Q1 2016 | $6,585,000 | -8.5% | 478,900 | +12.1% | 0.00% | -50.0% |
| Q4 2015 | $7,198,000 | +73.7% | 427,200 | +13.0% | 0.00% | +100.0% |
| Q3 2015 | $4,145,000 | -10.3% | 378,200 | +2.4% | 0.00% | 0.0% |
| Q2 2015 | $4,619,000 | +12.2% | 369,200 | -1.3% | 0.00% | 0.0% |
| Q1 2015 | $4,115,000 | -37.7% | 374,100 | -12.2% | 0.00% | 0.0% |
| Q4 2014 | $6,602,000 | +59.3% | 425,916 | +24.1% | 0.00% | 0.0% |
| Q3 2014 | $4,144,000 | -2.5% | 343,300 | +3.6% | 0.00% | 0.0% |
| Q2 2014 | $4,250,000 | -74.8% | 331,500 | -76.2% | 0.00% | -75.0% |
| Q1 2014 | $16,888,000 | -48.2% | 1,393,400 | -51.5% | 0.00% | 0.0% |
| Q4 2013 | $32,620,000 | +118.9% | 2,874,000 | +101.5% | 0.00% | 0.0% |
| Q3 2013 | $14,902,000 | -57.4% | 1,426,000 | -52.9% | 0.00% | -20.0% |
| Q2 2013 | $34,972,000 | – | 3,027,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |